Global vs China CDMO: Q3 Growth Gap, Order Shift, and the Section 232 Repricing

With the Q3 earnings season closed, the two pure-play global benchmarks - Samsung Biologics and Lonza - sit alongside China's four (WuXi AppTec, WuXi Biologics, Pharmaron, Asymchem). Three rulers - growth gap, real order flow, and the 232 tariff - show China's supply chain was not dismantled by the tariff.

The 2026 Q3 earnings season is closed, and the two pure-play global CDMO benchmarks - Samsung Biologics and Lonza - reported alongside China's four (WuXi AppTec, WuXi Biologics, Pharmaron, Asymchem). Put six reports side by side and the question is richer than 'who grew faster': what exactly is the growth gap, are orders really shifting out of mainland China, and what pricing logic did the looming Section 232 tariff actually rewrite?

1. The growth gap: WuXi AppTec runs alone, the rest sit with the globals

Lined up, the starkest feature is internal divergence, not a camp divide. WuXi AppTec posted 9M revenue of RMB 45.54 bn (+38.6% YoY) and net profit to parent of RMB 19.40 bn (+60.6%), raising its full-year guidance to RMB 61.0-61.9 bn (continuing-business revenue +40%-42% YoY); in Q3 alone, revenue was RMB 16.64 bn (+38.0%) and net profit to parent RMB 8.32 bn (+136.7%). That growth puts it a full lap ahead.

The other three Chinese names sit in the 15%-20% band: WuXi Biologics H1 revenue RMB 11.79 bn (+18.4%, +23.4% in USD), net profit to parent RMB 2.44 bn (+4.3%); Pharmaron 9M revenue RMB 12.00 bn (+19.0%), net profit to parent RMB 1.25 bn (+9.3%); Asymchem 9M revenue RMB 5.395 bn (+16.5%), net profit to parent RMB 0.852 bn (+6.5%), guiding full-year revenue +19%-22%.

The two global benchmarks: Samsung Biologics Q3 revenue KRW 1.49 trillion (+18.5%) and raised its full-year revenue-growth guidance to 20% (from 15%-20%); Lonza H1 sales CHF 3.4 bn (+16.0% CER, +11.2% AER), with full-year CER growth guidance of 11%-12%.

State the conclusion first: the 'growth gap' is not a China-vs-global camp divide but a 'WuXi AppTec vs the rest' structural fault line. Excluding WuXi AppTec, the three Chinese names (15%-20%) sit in essentially the same band as Samsung (Q3 +18.5% / 20% FY) and Lonza (H1 +16% CER). What truly separates is WuXi AppTec's integrated CRDMO realisation cadence.

2. Order shift: paper dividends unfulfilled, real orders still flowing east

The Section 232 tariff places Korea (Samsung) and Switzerland (Lonza) in the 15% preferential tier while mainland China falls into the default 100%. In theory, 'friend-shoring' should push orders from mainland China toward Korea and Switzerland. Measured by the real ruler of new/backlog-order growth, the story inverts.

WuXi AppTec's continuing-business backlog reached RMB 76.74 bn at end-September (+36.4% YoY); WuXi Biologics' backlog was $25.1 bn, with the three-year backlog at $5.5 bn (~+30% YoY); Pharmaron's 9M new orders rose +30% (CDMO +40%, lab services +25%) and revenue from top-20 pharma customers +52.5% YoY; Asymchem's new orders kept double-digit growth. By contrast, Samsung Biologics' cumulative contract orders crossed $22 bn but that is a multi-year cumulative figure, not single-quarter new wins; Lonza does not disclose a specific backlog number, only qualifying double-digit platform growth.

Key read: by new/backlog-order growth, China's four broadly post 30%+, far above the gentle reallocation a friend-shoring shift would imply. Clients vote with their feet - on incremental modalities like ADC, peptides and CGT they still hand projects to China's supply chain. Samsung Biologics' tender offer for PolyPeptide (87.92% acceptance) is precisely to intercept WuXi's TIDES at the peptide (GLP-1) front, side-evidence that the main battlefield for incremental share is China's strength zone, not the tariff's preferential zone.

3. The 232 repricing: cost efficiency yields to supply-chain security

On April 2, 2026, under Section 232 of the Trade Expansion Act of 1962, the US imposed tariffs on imported patented drugs and their APIs: a default 100% ad valorem; 15% for the EU/Japan/Korea/Switzerland/Liechtenstein and 10% for the UK; 20% for those with an approved onshoring plan (automatically rising to 100% on April 2, 2030); and 0% for onshoring plus an MFN pricing agreement (through January 20, 2029). Generics, biosimilars, orphan drugs, plasma-derived products, nuclear medicines, cell and gene therapy (CGT), antibody-drug conjugates (ADC) and fertility treatments are exempt (0%). The policy has already triggered ~$400 bn in committed domestic pharma investment.

Three layers of impact on China's CDMOs: (1) limited direct hit - China's US exposure is mostly API exports and License-out (no physical export), and ADC, CGT and orphan drugs fall in the exempt zone; (2) structural headwind - Chinese capacity serving US-patent-drug orders faces 100% tariffs unless the client signed onshoring/MFN, risking passive disentanglement or a downgrade to 'In China for China'; (3) long-term compliance pressure - key starting materials (KSM) are already under monitoring, with duty exemptions bound to a 'trade-security framework / origin traceability' that substantively squeezes Chinese sites' room to take global frontier outsourcing.

The repricing logic: the 232 tariff is fundamentally a 'US re-industrialization' tool, shifting the global pharma supply-chain anchor from 'cost efficiency' to 'supply-chain security.' Near term, the exempt zone (ADC, CGT, non-patent peptide APIs) remains China's core bargaining chip - exactly the new-modality realisation zone described in T3; longer term, high-cost US domestic capacity plus the $400 bn commitment will lift the global CDMO pricing center, and China's 'technology + scale + cost' triangle becomes more valuable precisely in the exempt zone.

Section 232 rewrote the CDMO valuation anchor: it used to be who is cheaper, now it is who is 'securely reachable.' China's core base happens to sit in the exempt zone - that is luck, but also the payoff of a decade of technology accumulation.

4. Conclusion: one tier behind, but the core base sits in the exempt zone

Growth gap: WuXi AppTec leads by a tier; the rest of China sits with the globals. This is neither 'China crushing' nor 'the globe reversing' - it is WuXi AppTec's integration cadence leading.

Order shift: the paper friend-shoring dividend is unfulfilled; real incremental orders still grow fast and flow east. China's supply-chain 'technology + scale + cost' triangle is not dismantled by the tariff - at least not on incremental new modalities.

232 repricing: the structural headwind is real but offset by the exempt zone (ADC, CGT, peptides). China's long-term moat is in 'incremental new modalities' rather than 'stock patent drugs' - and the latter is exactly where Section 232 bites hardest. In other words, the tariff strikes China's least-dependent part and spares its sharpest part.

What is next

This is the fourth piece (T4) of the CXDMO 2026 Q3 in-depth series. Published: the Q3 panorama (T1), upstream equipment & consumables localization (T2), new-modality TIDES/ADC/CGT realisation (T3); the closer will break down the capex and capacity-expansion cycle (T5).